What We're Reading: Romney on Drug Prices; Kentucky Delays Work Requirements; Teva's Epinephrine Shortage

Senator Mitt Romney, R-Utah, warned PhRMA that he and his new colleagues are working to tackle the issue of high prescription drug prices; Kentucky is delaying the start of work requirement rules for a portion of its Medicaid population; despite its approval by the FDA last year, Teva’s generic version of an epinephrine autoinjector is not available at the largest pharmacies or through drug distributors.

Romney Tells PhRMA Changes in Drug Pricing Are Coming

Kentucky Delaying Start of Medicaid Work Rules

Teva's Epinephrine in Short Supply Months After Approval

Senator Mitt Romney, R-Utah, warned the Pharmaceutical Research and Manufacturers of America (PhRMA) that he and his new colleagues are working to tackle the issue of high prescription drug prices in a closed-door meeting, STAT News reported. The industry should be prepared to take part in participate in those discussions, he said.Kentucky is delaying the start of work requirement rules for a portion of its Medicaid population, the Associated Press reported. A federal judge blocked the rules last year, but the Trump administration approved them a second time in November. Some of the rules were to start April 1, but they will now begin no sooner than July 1, the state said.Despite its approval by the FDA last year, Teva’s generic version of an epinephrine autoinjector is not available at the largest pharmacies or through drug distributors, Reuters reported. The short supply means Teva cannot compete with Mylan in a roughly $750 million a year US market. Mylan’s EpiPen has also been in short supply since spring 2018. Teva did not say why its drug was in short supply.